<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37204123</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Cognitive dysfunction in patients with systemic lupus erythematosus. A cross-sectional study in a Brazilian sample.</ArticleTitle><Pagination><StartPage>900</StartPage><EndPage>909</EndPage><MedlinePgn>900-909</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231176794</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive dysfunction (CD) is frequently found in patients with systemic lupus erythematosus (SLE) and contributes to impairment in the patient's quality of life.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To study CD in a sample of patients and the possible associations with cumulative damage, disease activity, clinical/serological profile, and cumulative glucocorticoid dose.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Included in this study are 103 patients with SLE and 95 controls for cognitive performance through MoCA (Montreal Cognitive Assessment) and MMSE (Mini-Mental State Examination). Disease activity was measured by SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) and cumulative organ damage by SLICC/ACR/DI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index). CES-D (Center for Epidemiological Studies-Depression) scale was used to evaluate depression. Data on clinical and serological profile, treatment, and cumulative glucocorticoid dose were also collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with SLE had worse performance in the MoCA (<i>p</i> = 0.009) and MMSE (<i>p</i> = 0.01) than controls. The MoCA results showed that visuospatial and abstraction domains (<i>p</i> = 0.03 and <i>p</i> = 0.002, respectively) were impaired, and the MMSE results showed that language and spatial orientation were reduced (<i>p</i> = 0.002 and <i>p</i> = 0.01, respectively) when compared to controls. Both questionnaires (MoCA with r = -0.29 and MMSE r = -0.21) correlated negatively with SLICC/ACR/DI and the MoCA with SLEDAI (r = -0.22). No associations were found with cumulative glucocorticoid dose, degree of depression, and clinical or serological profile.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">According to the MoCA, visuospatial cognition and abstraction were impaired, and according to the MMSE, spatial orientation and language were impaired in patients with SLE. The CD was correlated with cumulative damage and disease activity. These findings demonstrate that both disease-activity and disease-injury associated CD is found broadly in SLE patients in a Brazilian population, supporting the prior reports of CD in other regional SLE populations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borba</LastName><ForeName>Eduardo A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Internal Medicine Post Graduate, Clinical Hospital, Federal University of Paran&#xe1;, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">28122</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scoto Dias</LastName><ForeName>Eduarda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Mackenzie Evangelical School of Medicine, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">146839</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tercziany Vanzin</LastName><ForeName>Jos&#xe9; Henrique</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Mackenzie Evangelical School of Medicine, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">146839</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira de Queiroz Junior</LastName><ForeName>Nelzi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mackenzie Evangelical School of Medicine, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">146839</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>Thiago Alberto Fg</ForeName><Initials>TAF</Initials><AffiliationInfo><Affiliation>Mackenzie Evangelical School of Medicine, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">146839</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skare</LastName><ForeName>Thelma</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mackenzie Evangelical School of Medicine, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">146839</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nisihara</LastName><ForeName>Renato</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1234-8093</Identifier><AffiliationInfo><Affiliation>Internal Medicine Post Graduate, Clinical Hospital, Federal University of Paran&#xe1;, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">28122</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Mackenzie Evangelical School of Medicine, Curitiba, Brazil.</Affiliation><Identifier Source="RINGGOLD">146839</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Positivo University, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">disease activity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37204123</ArticleId><ArticleId IdType="doi">10.1177/09612033231176794</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>